Analysts Set UroGen Pharma Ltd. (NASDAQ:URGN) PT at $38.20

UroGen Pharma Ltd. (NASDAQ:URGN) has earned a consensus recommendation of “Buy” from the seven analysts that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $35.67.

URGN has been the topic of several recent research reports. D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a report on Monday, March 10th. Scotiabank initiated coverage on shares of UroGen Pharma in a report on Wednesday. They issued a “sector outperform” rating and a $23.00 price objective for the company. HC Wainwright reduced their target price on shares of UroGen Pharma from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. Finally, LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They set a “buy” rating and a $31.00 price target for the company.

Insider Buying and Selling

In other news, General Counsel Jason Drew Smith sold 7,379 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the transaction, the general counsel now directly owns 26,468 shares of the company’s stock, valued at $294,853.52. The trade was a 21.80 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now directly owns 145,666 shares of the company’s stock, valued at $1,622,719.24. This represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of URGN. SG Americas Securities LLC increased its stake in UroGen Pharma by 701.8% in the first quarter. SG Americas Securities LLC now owns 162,514 shares of the company’s stock valued at $1,797,000 after purchasing an additional 142,245 shares in the last quarter. Rhumbline Advisers grew its stake in shares of UroGen Pharma by 4.3% in the 1st quarter. Rhumbline Advisers now owns 53,466 shares of the company’s stock valued at $591,000 after buying an additional 2,196 shares during the period. GAMMA Investing LLC increased its position in UroGen Pharma by 6,908.4% in the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company’s stock valued at $83,000 after buying an additional 7,392 shares in the last quarter. Wellington Management Group LLP raised its stake in UroGen Pharma by 7.0% during the 4th quarter. Wellington Management Group LLP now owns 146,953 shares of the company’s stock worth $1,565,000 after buying an additional 9,653 shares during the period. Finally, Toronto Dominion Bank bought a new position in UroGen Pharma in the fourth quarter worth approximately $18,628,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

UroGen Pharma Stock Down 3.3 %

Shares of NASDAQ URGN opened at $10.39 on Thursday. The company has a market cap of $478.92 million, a price-to-earnings ratio of -3.30 and a beta of 0.80. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. UroGen Pharma has a 12 month low of $8.94 and a 12 month high of $20.70. The stock has a 50-day moving average price of $10.52 and a two-hundred day moving average price of $11.23.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The company had revenue of $24.57 million for the quarter, compared to analyst estimates of $25.25 million. As a group, analysts forecast that UroGen Pharma will post -3.12 earnings per share for the current fiscal year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.